Precigen Shares Fall 20% in Premarket Trading
Precigen shares plunged 20% in premarket trading Monday. The decline comes ahead of Wednesday’s earnings and as Inovio’s newly approved rival challenges Precigen’s Papzimeos treatment.
Shares of Precigen (PGEN) plunged 20% in premarket trading on Monday, but retail buyout hopes persist ahead of Wednesday’s earnings as Inovio’s newly approved rival challenges Papzimeos, Precigen’s treatment for a rare disease that causes recurring airway growths.PGEN stock fell 19% in October, end…